Fig. 3

LncRNA ARST interacted with ALDOA to exert its functions in glioma development. A Schematic illustration of RNA pulldown followed by mass spectrometry assay to detect potential proteins interacting with ARST. B Potential binding proteins were listed based on the score of peptide identification from mass spectrometry assay. C ALDOA was detected by Western blot from the eluted proteins following RNA pulldown assay using biotinylated sense and antisense strands of ARST. D RIP assay was performed with extracts of U87MG cells using anti-ALDOA or mouse IgG. IgG served as the negative control. ARST enriched in anti-ALDOA and IgG pull-downs was determined relative to the input. E Schematic diagram of truncated biotin-labeled ARST RNA probe F RNA pulldown followed by western blot was performed to detect the binding affinity of truncated ARST with ALDOA. Western blot G and qRT-PCR H were performed to detect the expression levels of ALDOA in the ARST overexpressed cells compared to the control. I Graphic representation of relative ALDOA expression levels (TPM) in different tissues (GBM vs. GTEx, LGG vs. GTEx). GBM and LGG represented glioblastoma multiforme and low grade gliomas in the TCGA datasets. GTEx represented normal brain tissues in the GTEx database. J Overall and K disease free survivals of the glioma patients with relative low or high level of ALDOA expressions were assessed (cut-off value is 50%). L The correlation of the expressions between ALDOA and LINC00632 were displayed based on the TCGA database. Data were presented as the mean ± s.d. from three independent experiments (***P < 0.005)